Document:

Exhibit 10.1

Date: September 6, 2017

Board of Directors

Consumer Capital Group, Inc.

136-82 39th Ave, 4th Floor, Unit
B

Flushing, New York

 

Resignation as
Director

Dear Board of Directors,

I
hereby tender my resignation as Director of Consumer Capital Group, Inc., effective September 6, 2017. My resignation is not
the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Sincerely,

	/s/ Dong
Yao	 	 
	Dong
YaoExhibit

Exhibit 10.1

Amendment to EXCLUSIVE LICENSE Agreement
This Amendment to the Exclusive License Agreement, dated as of September 5, 2017 (the “Amendment”), by and between Mills Pharmaceuticals, LLC., a Delaware limited liability MPI (the “MPI”), and BioVascular, Inc., a Delaware MPI (the “BVI”), amends the Exclusive License Agreement, dated as of December 20, 2013, by and between the MPI and BVI (the “License Agreement”). Capitalized terms shall of the meaning set forth in the License Agreement unless otherwise set forth herein.
WITNESS:
WHEREAS, the MPI and the BVI wish to resolve the dispute regarding MPI’s Commercially Reasonable Efforts to Develop the controlled release formulation of anagrelide by making certain amendments to the License Agreement.
NOW, THEREFORE, for good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the MPI and the BVI hereby agree as follows:
		
	1.
	Royalties. Section 3.2(a) of the License Agreement is hereby amended by deleting the chart contained therein and substituting the following chart:

	
		
	Cumulative Net Sales1 in a Calendar Year ("Annual Net Sales")
	Rate

	Portion of Annual Net Sales under $100,000,000
	4%

	Portion of Annual Net Sales equal to or greater than $100,000,000
	6%

 In calculating the Annual Net Sales for the purposes of determining the applicable royalty rate, Annual Net Sales shall include the cumulative Net Sales of MPI, its Affiliates and all Sublicensees (including U.S. Sublicensees) in a calendar Year. For the avoidance of doubt, the Net Sales of U.S. Sublicensees shall not be included in the calculation of royalties due under Section 3.2(a).
		
	2.
	Milestone Payments. Section 3.5 of the License Agreement is hereby amended by adding after the last paragraph of Section 3.5 the following paragraph:

3.Subject to payments to be made to Comerica Bank pursuant to Section 3.8, MPI shall make the following payments (“Advance Payments”) to BVI: (i) two hundred thousand dollars ($200,000) with one hundred thousand dollars ($100,000) of such amount paid to Comerica Bank, all such payments being made on or before October 31, 2017, and (ii) one hundred fifty thousand dollars ($150,000) within 30 days after the Effective Time as that term is defined in the Agreement and Plan of Merger and Reorganization dated August 7, 2017 by and among Galena Biopharma, Inc., Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc., Galena Bermuda Merger Sub, Ltd., and SELLAS Life Sciences Group Ltd. but no later than December 31, 2017.  Such Advance payments shall credited against the applicable Milestone Payments set forth in the first paragraph of this Section 3.5. 

4.Sublicenses. Section 3.10 of the License Agreement is hereby amended by adding after the first paragraph of Section 3.10 the following paragraph:

  In the event MPI sublicenses to Third Parties any rights under BVI Technology, MPI shall pay BVI the following payments:
	
		
	Sublicense to Third Party prior to first patient enrolled in Phase 3 trial of controlled release formulation of anagrelide for patients with essential thrombocythemia 
	25% of any cash received by MPI for upfront fess or milestone payments

	Sublicense to Third Party after first patient enrolled in Phase 3 trial of controlled release formulation of anagrelide for patients with essential thrombocythemia
	17.5% of any cash received by MPI for upfront fess or milestone payments

		
	5.
	Diligence. Section 4.5 of the License Agreement is hereby amended by adding after the first paragraph of Section 4.5 the following paragraph:

In the event the first patient is not enrolled in the Phase 3 trial of controlled release formulation of anagrelide for patients with essential thrombocythemia by December 31, 2018, BVI shall have the right to terminate all rights and licenses granted to MPI under this Agreement and none of the advanced milestone payments set forth in Section 2 of this Amendment shall be repaid to MPI. 
		
	6.
	Notices.  Section 12.4 of the License Agreement is amended so that notices to the MPI will be address or directed as follows:

Galena Biopharma Inc., 2000 Crow Canyon Place, Suite 380, San Ramon, CA 94583; attention: Thomas J. Knapp, Interim General Counsel; telephone: 925-498-7734; email: tknapp@galenabiopharma.com.
		
	7.
	Full Force and Effect.  The License Agreement remains in full force and effect as amended by this Amendment. 

(Signature page on the next page)

IN WITNESS WHEREOF, the parties hereto have signed this Amendment on the date first above written.
MILLS PHARMACEUTICALS, LLC
By: /s/ Stephen F. Ghiglieri                        
Name:    Stephen F. Ghiglieri                    
Title: Interim Chief Executive Officer and Chief Financial Officer                    

BIOVASCULAR, INC.
By:  /s/ John H. Parrish                        
Name:    John H. Parrish                    
Title: President and Chief Executive OfficerEX-10.1

 Exhibit 10.1 

SECOND AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT 

This SECOND AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT (this “Amendment”), dated as of September 7, 2017 and
effective as of August 31, 2017, amends that certain Securities Purchase Agreement, dated as of October 31, 2016, as amended by the First Amendment to the Securities Purchase Agreement, dated as of July 14, 2017 (the
“Agreement”), by and among American Midstream Partners, LP, a Delaware limited partnership (“AMID”), Magnolia Infrastructure Holdings, LLC, a Delaware limited liability company (the “Purchaser”),
and, solely with respect to Section 3 of this Amendment, High Point Infrastructure Partners, LLC, a Delaware limited liability company (“High Point”), and Magnolia Infrastructure Partners, LLC, a Delaware limited liability
company (“Magnolia”). Capitalized terms used and not defined herein shall have the respective meanings ascribed thereto in the Agreement. 

WHEREAS, the parties hereto have previously executed and delivered the Agreement; 

WHEREAS, Section 7.3(b) of the Agreement provides that the Agreement may be amended, modified or supplemented in writing signed by AMID
and the Purchaser; and 
 WHEREAS, AMID and the Purchaser wish to amend the Agreement in the manner set forth herein. 

NOW, THEREFORE, in accordance with Section 7.3(b) of the Agreement, the parties hereto agree as follows: 

1.    Amendment to Section 5.6. Section 5.6 of the Agreement is hereby amended and restated
in its entirety as follows: 
 “If the Series D Units remain outstanding at 5:00 p.m., New York City time, on
October 2, 2017, AMID shall promptly, but in no event later than October 4, 2017, issue to the Purchaser the Warrant in the form attached hereto as Exhibit B.” 

2.    Amendment to the Partnership Agreement. The Purchaser, as the sole record holder of the Series D Units,
hereby consents to and approves the adoption of Amendment No. 6 to the Fifth Amended and Restated Agreement of Limited Partnership of American Midstream Partners, LP (as amended, the “Partnership Agreement”), substantially in
the form attached hereto as Exhibit A-1, to be entered into and effectuated by the General Partner on the date hereof. Such consent and approval shall be deemed to satisfy any
requirements for approval of a majority of the Outstanding Series D Preferred Units under Section 13.3(c) of the Partnership Agreement. 

3.    Series D Call Exercise Notice. In accordance with Section 7.3(b) of the Partnership Agreement, High
Point, as the sole record holder of the Series A-1 Convertible Preferred Units of the Partnership, Magnolia, as the sole record holder of the Series A-2 Convertible
Preferred Units of the Partnership, and the Purchaser, as the sole record holder of the Series C Convertible Preferred Units of the Partnership, hereby consent to and approve the exercise by the Partnership of the Series D Call Right (as defined in
the Partnership Agreement), at any time on or prior to October 2, 2017, and as to any portion of the outstanding Series D Preferred Units outstanding at the time a Series D Call Exercise Notice (as defined in the Partnership Agreement) is
delivered. 

  
 1 

 4.    Waiver. The Purchaser hereby waives any prior breach or default
under the Agreement in connection with AMID’s obligations under Section 5.6 of the Agreement. 

5.    Effect of the Amendment. Each Party acknowledges that this Amendment constitutes an amendment to the
Agreement as contemplated by Section 7.3(b) of the Agreement. On or after the date hereof, any reference to the Agreement shall constitute a reference to the Agreement as amended hereby. Except as expressly modified or amended hereby, all terms
and provisions of the Agreement shall continue in full force and effect, and any conflict between the terms set forth herein and in the Agreement shall be governed by the terms of this Amendment. 

6.    Governing Law. This Amendment will be construed in accordance with and governed by the laws of the State of
New York. 
 7.    Execution of Amendment; Counterparts. This Amendment may be executed in any number of
counterparts and by the parties hereto in separate counterparts, each of which counterparts, when so executed and delivered, shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one and the same
Amendment. 
 [The remainder of this page is intentionally left blank.] 

  
 2 

 IN WITNESS WHEREOF, the Parties have entered into this Amendment as of the date first written
above, effective as of August 31, 2017. 
  

			
	American Midstream Partners, L.P.
	
	By: American Midstream GP, LLC
	Its: General Partner
		
	By	 	 /s/ Eric Kalamaras

	Name:	 	Eric Kalamaras
	Title:	 	 Senior Vice President and Chief
 Financial
Officer

 [Signatures continued on next page.] 

  
 [Signature page to Second
Amendment to Securities Purchase Agreement] 

 
			
	Magnolia Infrastructure Holdings, LLC
		
	By	 	 /s/ Daniel A. Revers

	Name:	 	Daniel A. Revers
	Title:	 	President
	
	Solely with respect to Section 3 of this Amendment:
	
	Magnolia Infrastructure Partners, LLC
		
	By	 	 /s/ Daniel A. Revers

	Name:	 	Daniel A. Revers
	Title:	 	President
	
	Solely with respect to Section 3 of this Amendment:
	
	High Point Infrastructure Partners, LLC
		
	By	 	 /s/ Daniel A. Revers

	Name:	 	Daniel A. Revers
	Title:	 	President

 Exhibit A-1 

Amendment No. 6 to Fifth Amended and Restated Agreement of Limited Partnership of American Midstream Partners, LP 

 AMENDMENT NO. 6 TO 

FIFTH AMENDED AND RESTATED AGREEMENT OF LIMITED 

PARTNERSHIP OF 

AMERICAN MIDSTREAM PARTNERS, LP 

This Amendment No. 6 (this “Amendment”) to the Fifth Amended and Restated Agreement of Limited Partnership of
American Midstream Partners, LP (the “Partnership”), dated as of September 7, 2017, as amended by Amendment No. 1 to the Fifth Amended and Restated Agreement of Limited Partnership of the Partnership, dated as of
May 1, 2016, as amended by Amendment No. 2 to the Fifth Amended and Restated Agreement of Limited Partnership of the Partnership, dated as of October 31, 2016, as amended by Amendment No. 3 to the Fifth Amended and Restated
Agreement of Limited Partnership of the Partnership, dated as of March 8, 2017, as amended by Amendment No. 4 to the Fifth Amended and Restated Agreement of Limited Partnership of the Partnership, dated as of May 25, 2017, as amended
by Amendment No. 5 to the Fifth Amended and Restated Agreement of Limited Partnership of the Partnership, dated July 14, 2017 (as so amended, the “Partnership Agreement”), is hereby adopted effective as of
August 31, 2017 by American Midstream GP, LLC, a Delaware limited liability company (the “General Partner”), as general partner of the Partnership, pursuant to the authority granted to it in
Section 13.1 of the Partnership Agreement. Capitalized terms used but not defined herein have the meaning given such terms in the Partnership Agreement. 

WHEREAS, Section 13.1(g) of the Partnership Agreement provides, in part, that the General Partner, without the
approval of any Partner, may amend any provision of the Partnership Agreement in connection with the creation, authorization or issuance of any class or series of Partnership Interests and options, rights, warrants, appreciation rights, tracking and
phantom interests or other economic interests in the Partnership relating to Partnership Interests; 
 WHEREAS,
Section 13.3(c) of the Partnership Agreement provides that, if the General Partner determines an amendment adversely affects one or more classes of Partnership Interest, as compared to other classes of Partnership
Interests, in any material respect, such amendment shall only be required to be approved by the adversely affected class or classes; 

WHEREAS, the Board of Directors of the General Partner has determined that the standards specified in Section 13.1(g) and
Section 13.3(c) are satisfied with respect to the amendments to the Partnership Agreement to be made by this Amendment upon approval of Record Holders of a majority of Outstanding Series D Units; 

WHEREAS, the Partnership and Magnolia Infrastructure Holdings, LLC (“MIH”) have entered into that certain
Second Amendment to the Securities Purchase Agreement dated the date hereof and effective as of August 31, 2017 (the “SPA Amendment”); 

WHEREAS, MIH is the sole record holder of the Outstanding Series D Units and, pursuant to the SPA Amendment, has approved this
Amendment; and 
 WHEREAS, the General Partner deems it in the best interests of the Partnership to effect this Amendment in order
to effect amendments to the Partnership Agreement necessary to reflect the terms of the SPA Amendment. 

  
 1 

 NOW THEREFORE, the General Partner does hereby amend the Partnership Agreement as
follows: 
  

	A.	Amendment. The Partnership Agreement is hereby amended as follows: 

  

	 	a.	Section 1.1 is hereby amended to amend and restate the following definitions in their entirety: 

“Series D Unit Purchase Agreement” means the Securities Purchase Agreement dated as of October 31, 2016, by and
between the Partnership and MIH, as amended by the First Amendment to the Securities Purchase Agreement dated as of July 14, 2017 and the Second Amendment to the Securities Purchase Agreement dated as of September 7, 2017. 

“Series D Warrant Start Date” means October 2, 2017. 

 

	B.	Agreement in Effect. Except as hereby amended, the Partnership Agreement shall remain unchanged and unmodified and in full force and effect. 

 

	C.	Applicable Law. This Amendment shall be construed in accordance with and governed by the laws of the State of Delaware, without regard to principles of conflicts of laws that would apply the laws of any
other state. 

  

	D.	Severability. Each provision of this Amendment shall be considered severable and if for any reason any provision or provisions herein are determined to be invalid, unenforceable or illegal under any
existing or future law, such invalidity, unenforceability or illegality shall not impair the operation of or affect those portions of this Amendment that are valid, enforceable and legal. 

 

	E.	Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be any original, but such counterparts shall together constitute but one and the same instrument.

 [THE REMAINDER OF THIS PAGE INTENTIONALLY BLANK] 

  
 2 

 IN WITNESS WHEREOF, the undersigned has executed this Amendment as of the date first written
above and effective as of August 31, 2017. 
  

			
	American Midstream Partners, LP
	
	By: American Midstream GP, LLC,
	       its General Partner
		
	By:	 	 /s/ Eric T. Kalamaras

	Name:	 	Eric T. Kalamaras
	Title:	 	Senior Vice President and Chief Financial Officer

  
 [Signature Page to
Amendment No. 6 to Limited Partnership Agreement.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]